Intravesical chemotherapy agent
This page covers all Intravesical chemotherapy agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (mitomycin C mechanism).
Targets
Phase 3 pipeline (1)
- UGN-102 · UroGen Pharma Ltd. · Oncology
UGN-102 is a mitomycin C-based intravesical therapy that delivers chemotherapy directly to the bladder urothelium to treat non-muscle invasive bladder cancer.
Patent intelligence
- intravesical chemotherapy agent patent landscape — aggregated cliff calendar, attackable patents, originator estates